Sign in to continue:

Friday, January 30th, 2026

Fortress Minerals Ltd. 2025-2026 Outlook: Lower Iron Ore Prices, Delayed Mengapur Growth & Updated Target Price (KGI Research)

KGI Securities (Singapore) Pte. Ltd., December 2, 2025

Excerpt from KGI Securities report.

Report Summary

  • KGI Securities maintains an OUTPERFORM rating on Fortress Minerals but lowers the target price to S\$0.27, reflecting a more cautious outlook due to structurally softer iron ore prices expected through 2030 and the delayed contribution from the Mengapur project.
  • Recent results show solid volume growth but margin pressure from lower average selling prices and rising costs, with near-term upside dependent on a strong iron ore market or faster-than-expected progress at Mengapur.
  • Fortress’s realized pricing has fallen from a premium to a discount versus the iron ore benchmark, limiting margin recovery even if prices stabilize; sales growth is now driven mainly by Bukit Besi until Mengapur ramps up, likely from FY2027.
  • Valuation is based on a blend of discounted cash flow (DCF) and EV/resource approaches, both cut from previous levels; the risk/reward is now seen as balanced, with key catalysts being iron ore price surprises, project progress, or strategic partnerships.
  • Key risks include iron ore price volatility, regulatory and execution risks at Mengapur, operational challenges at Bukit Besi, customer concentration, and macroeconomic or FX fluctuations.

Above is an excerpt from a report by KGI Securities. Clients of KGI Securities can be the first to access the full report from the KGI Securities website: https://www.kgieworld.sg

YZJSGD Acquires 34% Stake in Tsuneishi Group’s China Unit for RMB 833.1 Million

Date of Report: September 30, 2024Broker Name: CGS International Securities Acquisition of 34% Stake in Tsuneishi Group’s China UnitYZJSGD has announced the acquisition of a 34% stake in the China unit of Tsuneishi Group....

Hyphens Pharma International (HYP) 2025 Outlook: Higher Margins, Portfolio Optimization & Growth Targets in Southeast Asia

CGS International August 20, 2025 Hyphens Pharma International: Strategic Portfolio Shift Drives Margin Growth Despite Revenue Dip Executive Summary: Navigating a Pivotal Transition in Hyphens Pharma International Hyphens Pharma International (SGX: HYP), a leading...

Foshan Haitian Flavouring 2Q25 Results Preview: Slower Sales Growth but Higher Profit Margins Ahead

CGSI RESEARCH July 10, 2025 Foshan Haitian Flavouring: Navigating Slower Growth, Margin Expansion, and Strategic Innovation in 2025 Executive Summary Foshan Haitian Flavouring, the leading condiments producer in China, enters the second half of...